FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
Alderley Park’s Glasshouse digital hub opens its doorsThe new Glasshouse hub for digital and tech companies has officially opened at the former AstraZeneca site in Share XAlderley Park’s Glasshouse digital hub opens its doorshttps://pharmaphorum.com/news/alderley-parks-glasshouse-digital-hub-opens-its-doors/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
AZ shares slide after warning over coronavirus impactShares in AstraZeneca were sharply down this morning after it warned that the hit from the COVID-19 coronavirus Share XAZ shares slide after warning over coronavirus impacthttps://pharmaphorum.com/news/az-shares-slide-after-warning-over-coronavirus-impact/
FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
NICE rejects MSD/Pfizer’s combination in untreated kidney cancerNICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) Share XNICE rejects MSD/Pfizer’s combination in untreated kidney cancerhttps://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/
Takeda invests in patient-centric data firm SeqsterUS startup Seqster, which it claims to “put the person at the centre of healthcare”, has just attracted Share XTakeda invests in patient-centric data firm Seqsterhttps://pharmaphorum.com/news/takeda-invests-in-patient-centric-data-firm-seqster/
CMO Nathwani out as Sanofi’s Hudson slims top executive teamThe revamp of French drugmaker Sanofi under new chief executive Paul Hudson has filtered up to top management, Share XCMO Nathwani out as Sanofi’s Hudson slims top executive teamhttps://pharmaphorum.com/news/cmo-nathwani-out-as-sanofis-hudson-slims-top-executive-team/
Futura seeks EU approval of erectile dysfunction gel as medical deviceUK biotech Futura Medical has said it will seek approval for its MED3000 topical treatment for erectile dysfunction Share XFutura seeks EU approval of erectile dysfunction gel as medical devicehttps://pharmaphorum.com/news/futura-seeks-eu-approval-of-erectile-dysfunction-gel-as-medical-device/
